Association of Annual N-Terminal Pro-Brain Natriuretic Peptide Measurements With Clinical Events in Patients With Asymptomatic Nonsevere Aortic Stenosis: A Post Hoc Substudy of the SEAS Trial

What Was Tested

This randomized controlled trial paper looks at BNP (Nesiritide).

To assess the association of annual NT-proBNP measurements with clinical outcomes in patients with nonsevere AS.

Why It Was Studied

Recent studies have questioned the presumed low-risk status of patients with asymptomatic nonsevere aortic stenosis (AS).

Whether annual N-terminal pro-brain natriuretic peptide (NT-proBNP) measurements are useful for risk assessment is unknown.

Who Took Part

The study group was 1873 patients.

By PubMed's age tags, the people studied were older adults, both men and women.

SEAS included 1873 patients with asymptomatic AS not requiring statin therapy with transaortic maximal flow velocity from 2.5 to 4.0 m/s and preserved ejection fraction.

How the Study Was Run

The design is described as randomized, double-blind and multicenter.

Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.

Blinding on both sides kept the patients and researchers unaware of who received BNP (Nesiritide).

More than one site took part, so the patients came from several places.

Analysis of annual NT-proBNP concentrations in the multicenter, double-blind Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) randomized clinical trial was performed.

SEAS was conducted from January 6, 2003, to April 1, 2008.

Blood samples were analyzed in 2016, and data analysis was performed from February 10 to October 10, 2021.

What Was Measured

Whether annual N-terminal pro-brain natriuretic peptide (NT-proBNP) measurements are useful for risk assessment is unknown.

Topics PubMed links to this paper include Aortic Valve Stenosis, Biomarkers, Natriuretic Peptide, Brain, Oceans and Seas, Peptide Fragments and Prognosis.

What This Means in Plain Language

The paper is a randomized, double-blind and multicenter study of BNP (Nesiritide) in 1873 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (JAMA cardiology), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.